CVI Accepts, published online ahead of print on 14 May 2008
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calderaro, A.
Right arrow Articles by Dettori, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calderaro, A.
Right arrow Articles by Dettori, G.

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00025-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Evaluation of Toxoplasma gondii IgG and IgM assays on the new VIDIA® instrument

Adriana Calderaro*, Giovanna Piccolo, Simona Peruzzi, Chiara Gorrini, Carlo Chezzi, and Giuseppe Dettori

Department of Pathology and Laboratory Medicine, Section of Microbiology, University of Parma, Viale A. Gramsci, 14 - 43100 Parma, Italy

* To whom correspondence should be addressed. Email: adriana.calderaro{at}unipr.it.


arrow
Abstract

The new VIDIA® system is a fully automated system based on chemiluminescence and antigen bound to magnetic microparticles which allows a fast measurement of Toxoplasma gondii specific immunoglobulin G (IgG) and immunoglobulin M (IgM) levels. The analytical performance of the VIDIA Toxo IgG and IgM assays was evaluated in comparison with the automated VIDAS®, AxSYM® and LIAISON® Toxo IgG and IgM assays. The comparative evaluation was performed on 204 frozen sera belonging to 166 subjects and on 201 fresh sera collected from 198 subjects. For VIDIA Toxo IgG, sensitivity was 100% both in the retrospective and prospective studies and specificity was 98.39% in the retrospective and 100% in the prospective study, respectively. The sensitivity of the other three Toxo IgG assays was 100% and the specificity ranged from 96.77% to 100%. For VIDIA Toxo IgM, sensitivity and specificity were 100%, both in the retrospective and prospective studies. The overall sensitivity and specificity of the other three Toxo IgM assays ranged from 80% to 100% and from 99.44% to 100%, respectively. In our study VIDIA revealed excellent sensitivity (100% both for IgG and IgM assays) and good specificity (99.25% for IgG and 100% for IgM assay).